🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safely Reduce Cystoscopic Evaluations for Hematuria Patients

RecruitingNAAges any - anyAllErasmus Medical Center
NCT06026189 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field * Male patients ≥40 years * Female patients ≥50 years Exclusion Criteria: * History of urothelial bladder- or urinary tract cancer * Presence of macroscopic (visible) hematuria * Woman who is or may be pregnant
💊

What it tests

  • urine-first strategy
📍

Where

1 site
SeARCH-trial Pijpers
Rotterdam, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy